WHAT IS OVA1TM OVARIAN TUMOR TRIAGE TEST?

WHAT IS OVA1TM OVARIAN TUMOR TRIAGE TEST?

A qualitative immunoassay test that produces a 0 to 10 score based on changes identified in 5 biomarker proteins (transthyretin, apolipoprotein A1, β2-microglobulin, transferrin, and CA-125 II cancer antigen) that increase when ovarian malignancy is present. Test results use the OvaCalcTM, a proprietary method to combine the results of the serum levels of the 5 proteins into a single score indicating risk of malignancy. Sensitivity is highest (96%) in women who are postmenopausal and lowest (89%) in women who are premenopausal. In all women, sensitivity is 92%. The sensitivity of 89% for OVA1 is higher than CA-125 (60%), and specificity is low (43%). This could result in referrals of benign conditions to gynecologic oncology surgeons; however, it would not cause added risk to the client. A major benefit of using OVA1 over CA-125 is that the increased sensitivity identifies more than 70% of malignancies not identified using the American College of Obstetricians and Gynecologists guidelines for referral of patients with a pelvic mass. 

KNOWLEDGE BASE
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

X